BLUE - bluebird bio withdraws Zynteglo from German market cuts jobs

bluebird bio (BLUE) has decided to withdraw Zynteglo (betibeglogene autotemcel) for transfusion-dependent ?-thalassemia ("TDT") from the German market due to unsuccessful reimbursement negotiations.bluebird says the price offered by German authorities didn't reflect the value offered by the therapy.However, the company says it is continuing reimbursement negotiations with other European countries.As a result, bluebird plans to reduce its workforce, primarily in Europe, though the company didn't provide figures.bluebird also reported that an investigation into a suspected  case of myelodysplastic syndrome reported in its Phase 1/2 study of LentiGlobin for sickle cell disease concluded that the patient actually experienced transfusion-dependent anemia.The company also says that clinical holds currently on the HGB-207 and HGB-212 clinical studies of Zynteglo for ?-thalassemia potentially may be lifted by mid-year.bluebird shares are down 1.7% to $27.50 in premarket trading.

For further details see:

bluebird bio withdraws Zynteglo from German market, cuts jobs